✦ LIBER ✦

5-Fluorouracil's cytotoxicity is enhanced both in vitro and in vivo by concomitant treatment with hyperthermia and dipyridamole

✍ Scribed by Yoshihiko Maehara; Yoshihisa Sakaguchi; Ikuo Takahashi; Motofumi Yoshida; Hiroki Kusumoto; Hidetaka Masuda; Keizo Sugimachi

Book ID: 104887014
Publisher: Springer
Year: 1992
Tongue: English
Weight: 447 KB
Volume: 29
Category: Article
ISSN: 0344-5704
DOI: 10.1007/bf00685941

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Enhancement of 5-fluorouracil cytotoxici

Enhancement of 5-fluorouracil cytotoxicity by human thymidine-phosphorylase expression in cancer cells: In vitro and In vivo study

✍ Alexre Evrard; Pierre Cuq; Bruno Robert; Laurence Vian; André Pèlegrin; Jean-Pau 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 French ⚖ 428 KB 👁 2 views

BCNU cytotoxicity is enhanced by overexp

BCNU cytotoxicity is enhanced by overexpression of antioxidant enzymes in vitro and in vivo

✍ Christine J. Darby; Benjamin B. Smith; Ernest W.N. Lam; Larry W. Oberley 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 158 KB

Enhanced retention of cytosine arabinosi

Enhanced retention of cytosine arabinoside and its metabolites and synergistic cytotoxicity by sequential treatment with dipyridamole in L5178Y leukemia

✍ Jin-Long Yang; J. Courtland White; Robert L. Capizzi 📂 Article 📅 1990 🏛 Springer 🌐 English ⚖ 326 KB

Heterogeneity of Thymic Lymphocytes, as

Heterogeneity of Thymic Lymphocytes, as Assessed by the Effects of Treatment with Cortisol, both in vivo and in vitro

✍ D. Bellamy; Hannah Alkufaishi 📂 Article 📅 1973 🏛 John Wiley and Sons 🌐 English ⚖ 915 KB

Treatment of colon and breast carcinoma

Treatment of colon and breast carcinoma cells with 5-fluorouracil enhances expression of carcinoembryonic antigen and susceptibility to HLA-A(*)02.01 restricted, CEA-peptide-specific cytotoxic T cells in vitro

✍ Pierpaolo Correale; Angelo Aquino; Antonio Giuliani; Monia Pellegrini; Lucia Mic 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 French ⚖ 155 KB 👁 1 views

## Abstract Cancer vaccines directed against tumor associate antigen (TAA) have produced encouraging results in preclinical models but not in cancer patients. A major limitation of this strategy is the relative degree of tolerance to these antigens and the low and heterogeneous tumor cell expressio